How to cite item

Thymidylate synthase gene polymorphism predicts disease free survival in stage II–III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy

  
@article{CCO24007,
	author = {Xiaona Su and Songlin Li and Hui Zhang and He Xiao and Chuan Chen and Ge Wang},
	title = {Thymidylate synthase gene polymorphism predicts disease free survival in stage II–III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy},
	journal = {Chinese Clinical Oncology},
	volume = {8},
	number = {3},
	year = {2019},
	keywords = {},
	abstract = {Background: The objective is to investigate whether thymidylate synthase gene TS 5'-UTR polymorphism of peripheral blood mononuclear cells are associated with clinical outcomes of patients with stage II–III rectal adenocarcinoma treated with adjuvant 5-fluorouracil (5-FU) chemotherapy in Chinese population. 
Methods: One hundred and seventeen pathologically diagnosed colorectal adenocarcinoma patients with stage II–III, who underwent curative resection and received 5-fluoropyrimidine-based adjuvant chemotherapy were enrolled to this study. The 5’-TSER polymorphisms determined from the peripheral blood mononuclear cells were measured by Direct Sequencing. Kaplan–Meier curves and log-rank tests were used for survival analysis. The independent prognostic factors influencing DFS and OS were estimated by Cox proportional hazards model. 
Results: The distribution of TS 5'-UTR polymorphisms ware 2.6% 2R/2R, 31.6% 2R/3R and 65.8% 3R/3R respectively, which was fitted with Hard-Weinberg equilibrium (χ2=0.345, P=0.558). Stage, N stage, number of mesenteric lymph node metastasis, KPS, and 5'-UTR polymorphisms (2R/2R/2R/3R vs. 3R/3R, P},
	issn = {2304-3873},	url = {http://cco.amegroups.com/article/view/24007}
}